Novo Nordisk A/S (NYSE:NVO) Sets New 52-Week Low - Here's What Happened

Key Points

• 52-week low: Novo Nordisk shares fell to a new 52-week low of $35.14 (last around $35.47), trading well below its 50‑day ($45.92) and 200‑day ($50.42) moving averages.
• Analyst outlook mixed: The consensus rating is "Hold" with a consensus price target of $65.56, even as several firms pared targets or downgraded the stock (Goldman cut its target to $41 from $63; Deutsche Bank and Weiss issued downgrades).
• Company fundamentals: Novo Nordisk reported an earnings beat (EPS $1.01 vs. $0.90 est., revenue $12.43B vs. $11.97B) and declared a $1.2751 dividend payable April 8 (ex‑dividend March 30), with a dividend payout ratio of ~52.7%.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $35.14 and last traded at $35.4710, with a volume of 474729 shares changing hands. The stock had previously closed at $36.04.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research report on Thursday. They issued a "peer perform" rating for the company. HSBC restated a "hold" rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. The Goldman Sachs Group restated a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, February 23rd. Finally, Weiss Ratings downgraded Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, March 18th. Four investment analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

The company has a market cap of $158.23 billion, a PE ratio of 10.24, a P/E/G ratio of 8.52 and a beta of 0.73. The company's fifty day moving average price is $45.92 and its 200 day moving average price is $50.42. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 718.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 52.74%.

Hedge Funds Weigh In On Novo Nordisk A/S

Large investors have recently modified their holdings of the company. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock valued at $712,000 after buying an additional 1,587 shares during the period. Rhumbline Advisers lifted its position in Novo Nordisk A/S by 3.2% during the second quarter. Rhumbline Advisers now owns 65,556 shares of the company's stock valued at $4,525,000 after buying an additional 2,017 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC lifted its holdings in shares of Novo Nordisk A/S by 63.7% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 61,585 shares of the company's stock valued at $4,251,000 after purchasing an additional 23,968 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.